He underwent left nephrectomy with removal of vena caval tumor on [**2101-6-28**] with pathology confirming renal cell carcinoma, clear cell type, nuclear grade 3 with extension into the perirenal fat focally, as well as invasion of the renal vein branches.
He underwent radiation therapy to the right and left iliac metastases.
He began high-dose IL-2 therapy on [**2101-8-29**], receiving 13 of 14 doses week 1, and 8 of 14 doses week 2, complicated by toxic encephalopathy, shock and shoulder pain.
He was readmitted in late [**Month (only) **] to begin cycle number 2 of high-dose IL-2 therapy, but persistent shoulder pain and decreased range of motion delayed treatment.
PAST MEDICAL HISTORY:  Metastatic kidney cancer as above; juvenile macular degeneration with legal blindness; status post multiple arthroscopic knee surgeries; GERD and status post appendectomy.
MEDICATIONS:  Flomax 0.4 mg at bedtime; Lexapro 20 mg at bedtime; aspirin 81 mg p.o.
daily; Colace 100 mg p.o.
; OxyContin mg q.a.m., 20 mg at bedtime; oxycodone 5-10 mg q.i.d.
pain; Tylenol p.r.n.
; Valium 5 mg at bedtime p.r.n.
insomnia; levothyroxine 25 mcg p.o.
daily and Protonix 20 mg p.o.
HOSPITAL COURSE:  Mr. [**Known lastname 82888**] was admitted and underwent interventional radiology central line placement to begin therapy.
After his first dose of IL-2, he required a fluid boluses to improve his blood pressure which were successful.
He subsequently was started on dopamine which was titrated upward to 6 mcg/kg per minute.
He required a second pressor [**Doctor Last Name 360**] of Neo-Synephrine which was increased to 3.5 mcg/kg per minute.
Given his borderline blood pressure, he was transferred to the ICU for potential need for further pressor agents.
Continuous blood pressure, bedside and central telemetry monitoring were instituted.
Further IL-2 therapy was held.
His blood pressure stabilized in the ICU and he was weaned off Neo-Synephrine and was weaned down on dopamine prior to returning to our floor the following morning.
He was subsequently weaned off dopamine without further shock or hypotension noted.
Other side effects during this week included nausea improved with antiemetic therapy; mucositis improved with oral agents, and development of an erythematous pruritic skin rash.
His shoulder pain was managed on OxyContin with p.r.n.
Metabolic acidosis was noted with a minimum bicarbonate of 19 improved with bicarbonate replacement intravenously.
He was anemic without need for packed red blood cell transfusion.
DISCHARGE MEDICATIONS:  Lasix 20 mg p.o.
daily x5 days or until you reach pretreatment weight; Tylenol 1-2 tablets q.i.d.
pain; lorazepam 0.5-1 mg t.i.d.
nausea, vomiting or anxiety; Benadryl 25-50 mg q.i.d.
pruritus; Compazine 10 mg q.i.d.
nausea/vomiting; Keflex 5 mg p.o.
x5 days; Lomotil 1-2 tablets q.i.d.
diarrhea; Eucerin cream topically; Sarna lotion topically; Lexapro 20 mg p.o.
at bedtime; aspirin 81 mg p.o.
daily; OxyContin 10 mg q.a.m., 20 mg p.o.
at bedtime; oxycodone 5-10 mg every 4 hours p.r.n.
pain; levothyroxine 25 mcg p.o.
